Nantahala Capital Management’s Janux Therapeutics JANX Stock Holding History

Nantahala Capital Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3M	Buy	+809,914	New	+$11.1M	0.41%	65

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nantahala Capital Management's JANX Position: Q1 2026 in Review

Nantahala Capital Management opened a new position in Janux Therapeutics (JANX) in Q1 2026: 809,914 shares worth $11.3M. The stake represents 0.41% of the portfolio and ranks #65 among its holdings.

190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Nantahala Capital Management held 809,914 shares of Janux Therapeutics worth $11.3M as of Q1 2026.
Janux Therapeutics was a new Nantahala Capital Management position in Q1 2026.
Janux Therapeutics made up 0.41% of Nantahala Capital Management's portfolio in Q1 2026, its #65 holding.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.